Systemic Lupus Erythematosus Treatment With N-Acetylcysteine (NAC)

Summary

This study focuses on individuals who have been diagnosed with systemic lupus erythematosus (SLE). The purpose of the study is to determine the medical effectiveness of the antioxidant N-acetylcysteine (NAC). Tiredness is one of the most common conditions in SLE. It is believed that NAC may improve tiredness by increasing the levels of glutathione, which has been found to be lacking in people with SLE. NAC also protects cells from poisonous body-damaging chemicals. Participants will receive either NAC or placebo (inactive substance). Blood donated during study visits will be used to determine whether levels of glutathione increase and immune cell function improves because of taking NAC. The impact of NAC on prednisone usage, liver function, bone marrow function, and overall tiredness will also be evaluated. NAC has been approved by the Food and Drug Administration (FDA) for various conditions, but its use in this study is investigational.


Inclusion Criteria

Not Available


Study Location(s)

Beverly


Full Title

Systemic Lupus Erythematosus Treatment with N-acetylcysteine

Details
Disease Type/Condition

Other

Principal Investigator

Wallace, Daniel

Age Group

Adult

Phase

II

IRB Number

STUDY00001975


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Other

Principal Investigator

Wallace, Daniel

Age Group

Adult

Phase

II

IRB Number

SNAC


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?